Why Is Zydus Lifesciences Share Price Falling? Key Reasons & Share Price Target 2026

Mon Apr 13 2026

Zydus Lifesciences share price is down -33% from its 52-week high of Rs 1,300, trading at Rs 860 as of April 2026. At its 52-week low of Rs 820, the stock has already given up significant gains — and investors are asking the same question: is this a buying opportunity or a value trap?

The Zydus Lifesciences share price falling is not random market noise. There are specific, identifiable reasons driving the decline — and this article examines each of them with real data, sector context, and the analyst consensus on what Zydus Lifesciences is worth.

Click Here — Get Free Investment Predictions on Univest.

Table of Contents

Why Is Zydus Lifesciences Share Price Falling? Key Reasons

Tap to Access Best Research Pieces on Univest.

Reason 1: Asacol HD Exclusivity Expiry — Revenue Impact

Zydus Lifesciences’ Asacol HD (mesalamine extended-release for ulcerative colitis) had US FDA exclusivity that provided significantly above-average margins. The expiry of this exclusivity and entry of generic competitors has removed a Rs 400-500 crore annualised high-margin revenue stream from FY26.

US generics exclusivities are finite. Zydus has historically been excellent at finding new exclusivities — but the pipeline timing means there’s always a gap between one exclusivity ending and the next beginning, creating earnings volatility.

Reason 2: US Generics Pricing Pressure

The US generic drug market continues to face structural pricing pressure as pharmacy benefit managers (PBMs) and large pharmacy chains consolidate and negotiate harder with generic manufacturers. Price erosion of 4-6% per year is the structural reality for most generic APIs and formulations.

Reason 3: Biologics and Biosimilar Pipeline Delays

Zydus has been building a biosimilar and biologics pipeline for the regulated US market. Several programmes, including insulin aspart (biosimilar insulin) and other injectable biologics, have faced FDA approval delays. These delays push out the expected revenue contribution from the higher-margin biosimilar business.

Reason 4: Saroglitazar — Delayed FDA Approval

Saroglitazar (for Non-Alcoholic Steatohepatitis / NASH) is Zydus’s most important innovative molecule in Phase 2/3 trials. Any delay in FDA approval timeline removes a key re-rating catalyst.

Reason 5: US Tariff Risk on Indian Pharma Exports

While the 26% US reciprocal tariff has an exception for pharmaceutical APIs, there is ongoing policy uncertainty. Any expansion of tariffs to finished pharma products would directly impact Zydus’s US revenue.

Zydus Lifesciences Financial Snapshot

Parameter	Value
CMP	Rs 860
52-Week High	Rs 1,300
52-Week Low	Rs 820
Decline from Peak	-33%
Market Cap	Rs 86,000 Cr
P/E Ratio	26x
P/B Ratio	4.8x
Promoter Holding	74.9%
FII Holding	10.4%
DII Holding	12.6%
Sector	Pharmaceuticals / Specialty Generics

Track Zydus Lifesciences live fundamentals and peer comparisons on the Univest Screener.

Download the Univest iOS App or Univest Android App for daily research updates.

Can Zydus Lifesciences Recover? Future Outlook

Zydus Lifesciences at Rs 860 and 26x P/E is one of the better-valued large-cap pharma stocks. The biosimilar pipeline (insulin aspart, adalimumab, etc.) represents significant optionality that is not fully priced in. Recovery to Rs 1,050-1,200 requires at least one key biosimilar approval in the US and stable base business performance. The founding Patel family’s 74.9% promoter holding provides governance confidence.

Zydus Lifesciences Share Price Target 2026

Subscribe to Univest Pro for SEBI-registered analyst recommendations.

Short-Term Target (3-6 Months)

Short-term Zydus Lifesciences share price target is Rs 820-960, based on current technical setup and near-term fundamental catalyst timeline. The 52-week low of Rs 820 is the key support level — a sustained break below this would be a significant bearish signal.

12-Month Analyst Consensus Target

Analyst consensus 12-month Zydus Lifesciences share price target is Rs 1,050-1,200, implying meaningful upside from the current Rs 860. This assumes the key headwinds identified in this article begin to resolve.

Long-Term Target (FY28)

In a full recovery scenario, the Zydus Lifesciences share price target for FY28 is Rs 1,400-1,600. This bull case requires the fundamental concerns in this article to show clear reversal over the next 4-6 quarters.

Frequently Asked Questions

Q1. Why is Zydus Lifesciences share price falling in 2026?

Zydus Lifesciences share price is falling primarily due to the reasons detailed in this article. The stock has declined -33% from its 52-week high of Rs 1,300 to the current Rs 860. Key factors include sector headwinds, earnings pressure, and broader market conditions. Review all factors before making any investment decision.

Q2. What is Zydus Lifesciences share price target 2026?

Analyst consensus 12-month Zydus Lifesciences share price target is Rs 1,050-1,200. Short-term target is Rs 820-960 and long-term FY28 target in a recovery scenario is Rs 1,400-1,600. These are analyst estimates and not guaranteed returns.

Q3. Should I buy Zydus Lifesciences at current levels?

This article does not provide personalised investment advice. Zydus Lifesciences is trading at Rs 860 with a 52-week range of Rs 820 to Rs 1,300. The risk-reward depends on your investment horizon and risk tolerance. Consult a SEBI-registered financial advisor before investing.

Q4. What is Zydus Lifesciences’s market cap and P/E ratio?

Zydus Lifesciences’s market capitalisation is Rs 86,000 Cr with a trailing P/E of 26x and price-to-book ratio of 4.8x. Promoter holding is 74.9%, FII 10.4%, DII 12.6%.

Q5. What can trigger recovery in Zydus Lifesciences share price?

Recovery triggers for Zydus Lifesciences include: resolution of the specific headwinds identified in this article, positive quarterly results showing reversal of stressed metrics, and broad market recovery. Monitor quarterly results and management commentary closely.

Disclaimer: For educational purposes only. Not investment advice. Consult a SEBI-registered financial advisor. Investments are subject to market risk.

For more analysis, visit Univest Blogs.